VA CMOP Program Achieves Highest Rating by J.D. Power
DLH Holdings Corp. (NASDAQ: DLHC) has announced that the Department of Veterans Affairs' Consolidated Mail Order Pharmacy (CMOP) program achieved the highest customer satisfaction rating in J.D. Power's 2022 U.S. Pharmacy Study. CEO Zach Parker emphasized the program's ability to maintain this satisfaction despite challenges like labor market issues and inflation. The study is based on thousands of customer responses and reinforces DLH's commitment to providing essential services to Veterans.
- DLH's CMOP program ranked highest in customer satisfaction according to J.D. Power's 2022 study.
- The company effectively manages significant challenges to fulfill timely prescriptions for Veterans.
- None.
ATLANTA, Oct. 13, 2022 (GLOBE NEWSWIRE) -- DLH Holdings Corp. (NASDAQ: DLHC) (“DLH” or the “Company”), a leading provider of innovative health research services and solutions to federal agencies, today announced that the Department of Veterans Affairs (“VA”) Consolidated Mail Order Pharmacy (“CMOP”) program ranked as the highest scoring mail order pharmacy for customer satisfaction when compared to commercial industry operations in J.D. Power’s 2022 U.S. Pharmacy Study.
“DLH works hand-in-hand with the VA to ensure hundreds of thousands of vital prescriptions are fulfilled on time each day for Veterans throughout the country, and it is gratifying to see widespread customer satisfaction persists despite difficult circumstances,” said Zach Parker, DLH President and CEO. “From unprecedented labor market challenges and union shutdown threats, inflationary pressures, and facility and supply-chain slowdowns, the VA CMOP program has faced and overcome significant obstacles in recent years in order to meet industry-best customer satisfaction standards.”
The rankings are based on responses from thousands of pharmacy customers who filled a prescription during the three months prior to the survey period. The entire J.D. Power consumer study is available at J.D. Power 2022 U.S. Pharmacy Satisfaction Study.
About DLH
DLH (NASDAQ:DLHC) delivers improved health and readiness solutions for federal programs through research, systems development, and innovative care processes. The Company’s experts in public health, performance evaluation, and health operations solve the complex problems faced by civilian and military customers alike, leveraging digital transformation, artificial intelligence, advanced analytics, cloud-based applications, telehealth systems, and more. With over 2,400 employees dedicated to the idea that “Your Mission is Our Passion,” DLH brings a unique combination of government sector experience, proven methodology, and unwavering commitment to public health to improve the lives of millions. For more information, visit www.DLHcorp.com.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:
This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or DLH`s future financial performance. Any statements that refer to expectations, projections or other characterizations of future events or circumstances or that are not statements of historical fact (including without limitation statements to the effect that the Company or its management “believes”, “expects”, “anticipates”, “plans”, “intends” and similar expressions) should be considered forward looking statements that involve risks and uncertainties which could cause actual events or DLH’s actual results to differ materially from those indicated by the forward-looking statements. Forward-looking statements in this release include, among others, statements regarding estimates of future revenues, operating income, earnings and cash flow. These statements reflect our belief and assumptions as to future events that may not prove to be accurate. Our actual results may differ materially from such forward-looking statements made in this release due to a variety of factors, including: the outbreak of the novel coronavirus (“COVID-19”), including the measures to reduce its spread, and its impact on the economy and demand for our services, are uncertain, cannot be predicted, and may precipitate or exacerbate other risks and uncertainties; the risk that we will not realize the anticipated benefits of acquisitions; the challenges of managing larger and more widespread operations; contract awards in connection with re-competes for present business and/or competition for new business; compliance with new bank financial and other covenants; changes in client budgetary priorities; government contract procurement (such as bid and award protests, small business set asides, loss of work due to organizational conflicts of interest, etc.) and termination risks; the ability to successfully integrate the operations of acquisitions; the impact of inflation and higher interest rates; and other risks described in our SEC filings. For a discussion of such risks and uncertainties which could cause actual results to differ from those contained in the forward-looking statements, see “Risk Factors” in the Company’s periodic reports filed with the SEC, including our Annual Report on Form 10-K for the fiscal year ended September 30, 2021, as well as subsequent reports filed thereafter. The forward-looking statements contained herein are not historical facts, but rather are based on current expectations, estimates, assumptions and projections about our industry and business.
Such forward-looking statements are made as of the date hereof and may become outdated over time. The Company does not assume any responsibility for updating forward-looking statements, except as may be required by law.
INVESTOR RELATIONS
Contact: Chris Witty
Phone: 646-438-9385
Email: cwitty@darrowir.com
FAQ
What did DLH Holdings announce on October 13, 2022?
What challenges did DLH mention regarding the VA CMOP program?
What is the significance of the J.D. Power 2022 U.S. Pharmacy Study for DLH?
How did DLH's CMOP program perform compared to commercial pharmacies?
